Clinical trials: Juvenile Arthritis
Juvenile Idiopathic Arthritis
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24…
- Trial name
- NCT01563185
- Testing
- 800 mg ibuprofen/26.6 mg famotidine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Amgen
Juvenile Idiopathic Arthritis
Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).
- Trial name
- NCT01513902
- Testing
- CP-690,550
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing…
- Trial name
- NCT04527380
- Testing
- Ixekizumab, Adalimumab
- Where
- 43 sites in Argentina, Belgium and 10 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic…
- Trial name
- NCT03031782
- Testing
- secukinumab
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Juvenile Idiopathic
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or…
- Trial name
- NCT00048542
- Testing
- OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 171 people
- Sponsor
- Abbott
Juvenile Rheumatoid Arthritis
Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
The primary objective of this study was to determine the efficacy of etanercept plus methotrexate vs methotrexate alone in pediatric patients with active polyarticular course juvenile rheumatoid arthritis (JRA).
- Trial name
- NCT03781375
- Testing
- Etanercept, Methotrexate
- Volunteers
- 25 people
- Sponsor
- Amgen
Arthritis, Juvenile
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with…
- Trial name
- GO-VIVA (NCT02277444)
- Testing
- Golimumab, Methotrexate
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 130 people
- Sponsor
- Janssen Research & Development, LLC
Anterior Uveitis, Arthritis, Juvenile Idiopathic
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
This study will examine the safety and effectiveness of a monoclonal antibody called humanized anti-Tac (HAT, also called daclizumab) to treat children and adolescents with uveitis (chronic inflammatory eye disease) associated…
- Conditions
- Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
- Trial name
- NCT00130637
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Uveitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear…
- Trial name
- NCT04088409
- Testing
- Baricitinib, Adalimumab
- Where
- 20 sites in France, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Juvenile Arthritis
Jointstrong Intervention for Juvenile Arthritis
This study is a randomized wait-list controlled trial with repeated measures. There will be two groups: (1) standard medical care (wait-list control), and (2) standard medical care plus the adjunctive Jointstrong pain coping…
- Trial name
- NCT01166750
- Testing
- CD-ROM, Wait-list Control Group
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Michael Rapoff, Ph.D.
Juvenile Idiopathic Arthritis
Efficacy Study Of Tofacitinib In Pediatric JIA Population
Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
- Trial name
- NCT02592434
- Testing
- CP-690,550 (tofacitinib)
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Osteoarthritis, Rheumatoid Arthritis
Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System
Prospective, multi-center clinical study to evaluate the clinical outcomes of the posterior stabilized design of the LCS® Complete Mobile-bearing Total Knee System
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis
- Trial name
- NCT00487565
- Testing
- Total knee arthroplasty
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- DePuy Orthopaedics
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Uveitis, JIA
Adalimumab in JIA-associated Uveitis Stopping Trial
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic…
- Trial name
- ADJUST (NCT03816397)
- Testing
- Adalimumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 87 people
- Sponsor
- Nisha Acharya
Juvenile Idiopathic Arthritis
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in participants aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate…
- Trial name
- SKYPP (NCT02776735)
- Testing
- Sarilumab
- Where
- 30 sites in United States, Argentina and 13 more
- Volunteers
- 102 people
- Sponsor
- Sanofi
Endocrine System Diseases
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
To evaluate the effect of increasing the growth hormone dose on the statural response To assess the value of early treatment during the course of arthritic disease by comparing the height acquired in the medium term by children…
- Trial name
- NCT00174291
- Testing
- Somatropin
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis
- Trial name
- NCT00807846
- Testing
- Celecoxib, Naproxen
- Where
- 39 sites in United States, Chile and 8 more
- Volunteers
- 201 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Arthritis Juvenile Idiopathic
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase.
- Trial name
- NCT03000439
- Testing
- In open-label phase: treatment with tofacitinib
- Where
- 52 sites in United States, Argentina and 17 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
Behavioral sleep problems such as sleep onset delays and frequent night wakings are common among young children (2-5 years). Children with a chronic health condition such as juvenile idiopathic arthritis (JIA) are even more prone…
- Trial name
- NCT04354337
- Testing
- Sleep Innovations for Preschoolers with Arthritis (SIPA)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington